A single corticosteroid injection to treat unilateral lateral epicondylalgia-tennis elbow-is linked to poorer outcomes after 1 year, according to a study published February 6 in JAMA.
A single corticosteroid injection to treat unilateral lateral epicondylalgia-tennis elbow-is linked to poorer outcomes after 1 year, according to a study published February 6 in JAMA.
Australian researchers conducted a 2 x 2 factorial, randomized, injection-blinded, placebo-controlled trial at a single university research center and 16 primary care settings in Brisbane, Australia. A total of 165 patients aged 18 years or older with unilateral lateral epicondylalgia lasting longer than 6 weeks’ duration were enrolled between July 2008 and May 2010. One-year follow-up was done in May 2011.
“Prior to our current study we knew that corticosteroid injections for tennis elbow produce a characteristic effect: high success rates early within 6 to 8 weeks but with high recurrence rates and protracted recovery thereafter. One of the often recommended solutions to the problem of high recurrence rates and protracted recovery is to add physiotherapy to the injection,” said corresponding author Bill Vicenzino, PhD, professor, and chair in sports physiotherapy and head of division of physiotherapy, School of Health and Rehabilitation Sciences, University of Queensland, St. Lucia, Australia.
In the study, the researchers evaluated the effect of combining injection and physiotherapy and found that (1) adding physiotherapy to corticosteroid injection does not solve the problem; (2) the corticosteroid medication appears to be responsible for 50% recurrence and delayed recovery (as was much less in the placebo injection); (3) the effect of physiotherapy is compromised when combined with steroid injection; and (4) those undertaking physiotherapy take significantly less analgesic or anti-inflammatory medication (half as much).
“We know from a previous study that the physiotherapy we studied is superior in regard to recurrence rates and longer-term recovery than injection, and almost as successful in the short term,” Vicenzino said. “Physiotherapy was shown to double the rate of recovery compared to taking a wait and see approach in that previous study.”
According to Vicenzino, previous studies showed high recurrence rates with corticosteroid injection (and protracted/delayed recovery) compared to physiotherapy and adoption of a wait-and-see approach.
“Conventional advice is that if recurrence and delayed recovery is of concern, then physiotherapy following injection should overcome this,” he said. “Be informed, that corticosteroid injections are associated with a high recurrence rate-twice plus as likely to recur compared to doing nothing or having physiotherapy.”
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.